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Summary The bioreductive cytotoxic agent SR 4233 (1,2,4-benzotriazine 3-amine 1,4-dioxide) has been
shown to markedly potentiate the cell killing of mouse tumours when combined with fractionated radiation
therapy. Differential metabolism under oxic compared to hypoxic conditions results in SR4233 exhibiting
selective cytotoxicity to hypoxic cells. This is thought to result from the production of a cytotoxic free radical
which is generated predominantly in the absence of oxygen. We have examined a way of enhancing the
effectiveness of this antitumour agent in vivo by artificially increasing the hypoxic fraction of tumours by hypoxic breathing. Mice are placed in a chamber containing 10% Oxygen 90% Nitrogen for 1 h after each
administration of SR 4233. Our results in the SCCVII tumour model indicate that this manoeuvre results in a
10-fold increase in antitumour effectiveness of SR 4233 when administered in a fractionated regime with
radiotherapy (8 x 2.5 Gy and 0.08 mmol kg-'), but not when a single treatment regime (1 x 20 Gy and
0.3 mmol kg-') is used. Mathematical modelling of this effect is used to illustrate this phenomenon and can be
used to predict the dependence of this type of therapy on the modification of tumour oxygenation.
For several decades hypoxic cells residing within tumours
have been regarded as a major obstacle to the effectiveness of
radiation therapy (Bush et al., 1978; Dische et al., 1983;
Henk, 1986). These same cells have also been suggested to
represent a population resistant to some chemotherapeutic
agents (Kennedy et al., 1980; Tannock & Guttman, 1981;
Teicher et al., 1990). Efforts have therefore been made to
'overcome' the resistance of hypoxic cells to radiation using a
variety of techniques including treatment with hyperbaric
oxygen (Churchill-Davidson et al., 1957; Sealy, 1991; Watson
et al., 1978), high LET radiation's (Withers, 1973) and most
recently, chemical hypoxic cell radiosensitisers (Adams et al.,
1976; Coleman, 1988; Dische, 1991). Hypoxic cell radiosen-
sitisers have, so far, shown only marginal benefit in clinical
settings primarily because of dose limiting toxicity (Coleman,
1988; Dische, 1991). However, the quest for improved
hypoxic cell radiosensitisers revealed a new class of com-
pounds which exhibit selective toxicity towards hypoxic com-
pared to oxygenated cells (Zeman et al., 1986). SR 4233
(1,2,4-benzotriazine 3-amine 1,4-dioxide) is a lead compound
of this new class of antitumour agents and is presently
undergoing Phase I clinical trials. The mechanism underlying
the selective toxicity of SR 4233 toward hypoxic cells is
believed to be due to the activation of SR 4233 by enzyme
mediated single electron transfer to a cytotoxic free radical
(Baker et al., 1988). When oxygen is present this radical is
'back oxidised' to the parent species possibly allowing other
reductive pathways, which do not result in free radical pro-
duction and hence cytotoxicity, to predominate thus amelior-
ating the toxicity to oxygenated cells (Baker et al., 1988;
Zeman et al., 1986).
The differential cytotoxicity of SR 4233 to oxic and
hypoxic cells can be exploited by using radiation to sterilise
oxygenated cells and a bioreductive cytotoxin such as
SR 4233 to kill the hypoxic cells of tumours. When these two
modalities are combined into a fractionated treatment regime
(a combination we have termed 'bioreductive radiotherapy')
a potent synergistic antitumour effect is obtained (Brown &
Lemmon, 1990). The combination of hypoxic cell cytotoxins
with radiation given in this form is predicted to be
significantly better at controlling tumours than even the most
potent hypoxic cell radiosensitiser or fully oxygenating all
tumour cells (Brown & Koong, 1991).
Since the oxygen concentration in tumours plays such a
crucial role in the bioactivation of SR4233 to the cytotoxic
free radical intermediate, we have examined ways in which
the antitumour activity of SR4233 can be modulated. We
exposed tumour bearing mice to a reduced oxygen atmos-
phere (10% oxygen, 90% nitrogen) for a period of 1 h after
treatment with radiation and SR 4233 and tested the effect of
this manoeuvre on both single and fractionated treatments in
vivo using a clonogenic assay. Our data show that the effect
of breathing 10% oxygen after radiation is to considerably
enhance the antitumour effect of SR4233, but this only
occurs with fractionated, not single dose treatment, radiation
treatment. Mathematical modelling indicate that this result is
expected provided there is complete reoxygenation and (its
counterpart for hypoxic cells, 'rehypoxiation') between
treatments.
Materials and methods
Mice and tumour
Male and female C3H/Km mice were bred and housed under
defined flora conditions in the Stanford Research Animal
Facility. Food (Wayne autoclavable rodent blox 8656,
Madison, WN) and water were available ad libitum except
for 1 h directly after treatment. The tumours used in this
study were SCCVII carcinomas (Hirst & Wood, 1982) intra-
dermally implanted onto the lower back of the mouse and
treated when they reached a geometric mean diameter of
8.2 ± 1.2 mm, approximately 17 days after implantation of
2 x 105 cells.
Irradiation
Mice were placed in lead shielding jigs which allowed the
tumour and a minimal amount of normal tissue to be
irradiated. The radiation; 250 kVp X-rays was delivered using
a Phillips RT 250 machine operating at 12.5 mA at a dose
rate of ca. 1.8 Gy min-' filtered with 0.35 mm Cu and having
a half-value layer of 1.3 mm Cu.
Reagents
SR4233 was supplied by Dr Michael Tracy (SRI Interna-
tional, Menlo Park, CA) and dissolved in physiological saline
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at a concentration of 4 and 6 mmol dm 3 respectively for the
fractionated and single dose treatments. DNAse and Col-
lagenase were obtained from Sigma St. Louis and Pronase
from Calbiochem, San Diego, CA. The doses of SR4233
were chosen to represent equal proportions of the maximum
tolerated dose for single amd multiple administration.
Treatment protocols
The single treatment comprised of animals receiving a dose
of 20 Gy followed immediately by a dose of 0.3 mmol kg-'
SR 4233 i.p. The mice were then placed in a clear plastic box
(14 x 14 x 30 cm) which was gassed with 10% oxygen, 90%
nitrogen at a flow rate of 5 1min-'. The mice remained in
this environment for 1 h after which they were returned to
normal cages under ambient conditions. The fractionated
treatments comprised 8 fractions of radiation, drug and low
oxygen breathing. Mice were administered 0.08 mmol kg-'
SR 4233 i.p. immediately after receiving 2.5 Gy radiation and
preceding 1 h of breathing 10% oxygen 90% nitrogen.
Treatments commenced at 8:30 am and 5:00 pm for four
consecutive days. Control animals were untreated other than
receiving saline injections instead of drug.
Excision assay
One day following the end of treatment the mice were killed
and tumour response assessed. To do this the tumours wee
aseptically removed and weighed, minced with curved scis-
sors and added to 10 ml of Hank's buffered saline solution
(Gibco, Grand Island, NY) containing 0.6 mgml-' Pronase,
0.2 mgml-' DNAse and 0.2 mgml-' Collagenase. This mix-
ture was agitated while being maintained at 37°C for 30 min
after which the cells were filtered through a steel mesh (pore
size approx 100gm) and centrifuged at 450 x g for 10 min.
The cell pellet was resuspended in 10 ml of Waymouths
medium (Gibco) containing 15% fetal calf serum (Irvine
Scientific, Irvine, CA). Cells excluding trypan blue were
counted and appropriate dilutions were made prior to
plating. The plated cells were then incubated at 37°C for 13
days in humidified air containing 5% CO2.
Assessment ofresponse
The action of SR 4233 in combination with radiation on
tumours was assessed using the in vivo - in vitro excision
assay. The number of trypan blue excluding cells extracted
per tumour following excision and dissociation was com-
pared to that from control animals in order to obtain an
estimate of the fractional yield (FY) of cells from the
tumours (i.e. total number of cells recovered from the treated
tumour divided by the total number of cells recovered from
the control tumours). The surviving fraction of the appar-
ently viable cells extracted from the tumour; i.e. the fraction
of cells which go on to form colonies, is calculated by
dividing the plating efficiency of the cells from treated
animals by the plating efficiency of the control population.
By multiplying the surviving fraction by the FY the relative
clonogenic cells per tumour is calculated. By examining the
three parameters, not only the ultimate outcome oftreatment
can be observed (the relative clonogenic cells per tumour),
but the contribution of the effects on the yield of cells from
the tumour as well as the reduction in clonogenicity of those
cells can be assessed.
Toxicity studies
To assess the effect of breathing 10% oxygen on the toxicity
of SR 4233 non-tumour bearing mice were administered
SR 4233 either as a single dose or fractionated doses in the
same way as the experiments detailed previously. Three mice
per dose group were used and the animals were closely
monitored for toxicity for up to 30 days after administration.
Animals were euthanised if found to be moribund or in
distress.
Assessment ofthe hypoxicfraction
The radiobiological hypoxic fraction was determined by com-
paring the survival of tumour cells irradiated in air breathing
animals with the survival of tumour cells made artificially
hypoxic by clamping (Van Putten & Kallman, 1968). Clamp-
ing was performed for approximately 5 min prior to the
irradiation period. The tumours were excised after the
irradiation and cell survival assessed by clonogenicity in vitro.
Two separate experiments were performed each with three
mice per dose group.
Results
Single treatment protocol
The pooled results of four experiments performed on male
and female mice are shown in Figure 1. Panel a shows values
of the relative clonogenic cells per tumour for the eight
different treatments. In the unirradiated groups (open sym-
bols) only the treatment involving both drug administration
and breathing of 10% oxygen resulted in a decreased value.
In the irradiated groups, the fraction of clonogenic cells was
reduced to about 10-3 in animals treated in air without
SR 4233 and no difference was seen in the group of animals
which breathed 10% oxygen after the irradiation. Tumours
from animals receiving SR 4233 and breathing air had a 10-
fold reduction in their number of clonogenic cells, but no
difference was noted between this group and the animals
which breathed 10% oxygen after the irradiation/drug treat-
ment. Panel b of Figure 1 shows the fractional yield of
trypan blue excluding cells extracted from the tumours.
Tumours from untreated control animals yielded a mean and
standard error of 6.06 ± 1.44 x 10' cells per tumour. None of
the treatments changed the yields of cells from the tumours.
Panel c of Figure 1 shows the surviving fraction of the cells
extracted from the tumours after different treatments. The
unirradiated tumours from mice breathing air or 10% oxygen
with or without administration of SR 4233 had similar mean
survival. The tumours from mice breathing air or 10%
oxygen after radiation treatment had a survival of about
2 x 10-3, but the survival of cells from tumours of mice
treated with SR 4233 was reduced by about a logarithm to
2 x 10-4. Additional treatment with 10% oxygen after
irradiation and SR4233 resulted in no further decrease in
survival.
Fractionated treatment protocol
The results of experiments performed using a fractionated
protocol are shown in Figure 2. Eight doses of 2.5 Gy with
or without SR 4233 (0.08 mmol kg-' per inj) were given over
4 days and followed the subsequent day by an excision assay.
Panel a shows the relative number of clonogenic cells per
tumour resulting from the different treatments. In the unir-
radiated groups only the tumours from mice treated with
both SR 4233 and breathing 10% oxygen had values reduced
from treatments without SR 4233. In the irradiated groups of
animals which subsequently breathed air or 10% oxygen the
number of clonogenic cells was reduced to about 2.5 x 10-3.
In mice treated with SR 4233 the clonogenic cell survival was
further reduced by about one logarithm to 2.5 x 10-4, and
further reduced to about 2.5 x 10-5 when 10% oxygen was
breathed in addition to the administration of SR4233. By
examining panel b of Figure 2 it can be seen that the yield of
cells was only sizably affected in unirradiated groups by the
treatment with both SR4233 and hypoxic breathing. The
apparent decrease in the fractional yield of cells of the
irradiated groups shown in panel b occurs because of the
effect of the fractionated irradiation on tumour growth,
because the tumour growth is retarded by the radiation
treatment and therefore the fractional yields are lower than
in the unirradiated groups. In the irradiated groups there is a
decrease in fractional yield of tumours from mice treated
with both SR 4233 and hypoxic breathing. Panel c shows theSR 4233 IS ENHANCED BY HYPOXIC BREATHING 1055
Air 10% Drug Drug
02 +Air + 10%
02
101
-a
z 0)
C
0
Co
._
1oo
10-'
10-2
, n
10-1
C
0
Co Q 10-2
m 10-3
._
25 10-4
0-5
I I I 'b
0
0
I l I
I I I 1.
.r .10
r I
I I l I
Air 10% Drug Drug
02 +Air + 10%
02
Figure 1 The response of tumours to a single treatment protocol comprising an X-ray dose of 20Gy and an administration of
SR 4233 (0.3 mmol kg-' i.p.). Open symbols represent the results from unirradiated tumours and closed symbols represent irradiated tumours. Results are from four separate experiments, two in female mice, two in males. Each treatment group in each experiment was comprised of four animals. Bars represent ± standard errors.
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Figure 2 The tumour response to a fractionated treatment protocol comprising eight fractions of 2.5 Gy X-rays followed by 0.08 mmol kg-' SR 4233 administration. Open symbols represent the results from unirradiated tumours and closed symbols
represent irradiated tumours. Results are from four separate experiments, two in female mice, two in males. Each treatment group in each experiment was comprised of four animals. Bars represent ± standard errors.
surviving fraction of the different treatment groups. All of
the unirradiated groups exhibited similar survival. Cells from
tumours of mice breathing air or 10% oxygen after the
irradiation showed similar survival of approximately
3 x 10-2. Tumours from mice receiving SR 4233 had a
reduced survival to about 5 x 10-3 and this was further
reduced by hypoxic breathing to about 1 x 10-3.
Toxicity studies
The toxicity of the different treatment protocols is shown in
Figure 3. The maximum tolerated (MTD) dose for mice
breathing air after receiving a single dose of SR4233 was
0.45 mmol kg-' and for mice breathing the low oxygen mix-
ture the MTD was reduced to 0.2 mmol kg-'. In the frac-
tionated studies the maximum tolerated total dose for
animals breathing air after receiving an SR 4233 administra-
tion was 1.28 mmol kg-' whereas when the animals breathed
lowered oxygen this was reduced to 0.8 mmolkg-'. There-
fore in the single dose studies SR 4233 was 2.25 times more
toxic to mice breathing 10% oxygen than air and in the
fractionated studies SR 4233 was 1.6 times more toxic to the
animals breathing reduced oxygen compared to air breathing.
Hypoxicfraction determination
Figure 4 shows the results of two experiments assessing the
surviving fraction of tumour cells after graded doses ofradia-
tion where the mice were either air breathing of where the
tumours were clamped to induce total anoxia. The hypoxic
fraction was determined from the separation of terminal
slopes of the anoxic and oxic curves. Using this technique
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Figure 3 Toxicity of SR 4233 after single and multiple administ-
ration. Mice were administered SR 4233 in an identical fashion to
that used in the unirradiated treatment schedules and observed
for 30 days. Open and closed circles represent mice receiving a
single dose of SR 4233 followed by normal air breathing of I h or
breathing 10% oxygen 90% nitrogen respectively. Open and
closed squares represent mice administered multiple doses of
SR 4233 to air breathing or mice breathing 10% oxygen 90%
nitrogen for 1 h after each dosing.
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Figure 4 Determination of the radiobiological hypoxic fraction
was performed by assessing the survival of cells derived from
tumours irradiated in air breathing mice (open symbols) com-
pared to the survival of cells from clamped tumours (closed
symbols). The separation of the terminal slopes indicated the
fraction of radiobiologically hypoxic cells as described by
Moulder and Rockwell, 1984 and is equal to 6.5% (95%
confidence limits of 2.82-14.79).
and fitting the data using the method described by Moulder
& Rockwell (1984) the tumours were found to have a
radiobiological hypoxic fraction of 6.5% (95% confidence
limits 2.82-14.76).
Discussion
The cytotoxicity of SR4233 is oxygen dependent. In vitro
studies show that SR4233 is between 40-150 times more
toxic (defined by dose ratios to produce equivalent cytotox-
icity) to cells in culture when exposed to the drug under
hypoxic compared to oxygenated conditions (Zeman et al.,
1986). In the present animal studies we show that in frac-
tionated therapy the anti-tumour effectiveness of SR 4233
can be enhanced by reducing the availability of oxygen post
irradiation. However, when a single treatment with radiation
and SR4233 is given no such enhancement in antitumour
effectiveness is observed.
The toxicity studies show that hypoxic breathing causes an
increase in toxicity in both single and fractionated treatment
regimes. In the single dose studies where hypoxic breathing
caused no increase in antitumour effectiveness, but caused
more toxicity it is clear that no therapeutic advantage is
indicated. In the case of the fractionated treatment the in-
crease in toxicity is countered by an increase in antitumour
effectiveness. Although full dose response curves would be
necessary to quantify the therapeutiv index, it appears that a
therapeutic advantage might be obtained with fractionated
therapy.
To determine whether the experimental data fit with
predictions on the interaction of radiation with a hypoxic
cytotoxin, we have modelled each situation. To do this we
have assumed that the total tumour cell population can be
regarded as being composed of two sub-populations each
with a different sensitivity to radiation and an overlapping
sub-set of cells that are sensitive to SR 4233. The
mathematical models are explained in the Appendix. For the
purpose of this discussion we have taken the hypoxic fraction
as equal to 5%, close to the actual hypoxic fraction deter-
mined in this study, the results of which are shown in Figure
4.
One important finding from the modelling studies is that
the model cannot account for the experimental data unless
the fraction of cells that is killed by the bioreactive drug is
greater than the fraction of cells that are radiobiologically
hypoxic. This is in agreement with in vitro studies of the
oxygen dependence of cell killing by SR4233 (Koch, C.J.,
personal communication, 1991 and Tosto & Brown, unpub-
lished). A separate function has therefore been invoked
which represents the fraction of the population that is sen-
sitive to the killing effect of the bioreductive drug. We have
called this fraction the chemosensitive hypoxic fraction (CHF
or *). Figure 5 shows the overall surviving fraction when
20Gy radiation and a bioreductive agent (such as SR4233)
is administered as a single fraction. If no drug is
administered the survival is approximately 10-3 which corres-
ponds to the experimental results seen in Figure 1. Experi-
mentally, when SR 4233 is administered, as in Figure 1, this
survival is reduced 10-fold. In order to obtain this reduction
in survival using the model shown in Figure 5 at least half
the population of the tumour must be sensitive to the
bioreductive agent, i.e. * must equal 0.5, and approximately
95% of the chemosensitive cells must be killed by the
administration of the drug. The model then predicts that
increasing the proportion of chemosensitive cells would inc-
rease the cell kill only marginally and this agrees with the
experimental data shown in Figure 1.
For fractionated irradiation with drug treatment the model
predicts a different result. Figure 6 shows the effect on sur-
viving fraction of the killing of different proportions of
hypoxic cells by the drug on tumours containing different
hypoxic fractions. When no killing is achieved by the drug
the survival is approximately 10-3, which corresponds
approximately to the survival seen experimentally and shown
in Figure 2 for tumours receiving 8 x 2.5Gy alone. The
survival after drug treatment in air breathing animals is
reduced about 10-fold. To model this assuming 4 equals 0.5
(as was the case in the single dose studies), then the drug
must kill about 50% of the cells (SFd = 0.5). The proportion
of cells killed by each dose in the fractionated treatment
would be expected to be smaller than that in the single
treatment because of the lower drug dose administered:
0.08 mmolkg-' vs 0.3 mmolkg-'. The model then predicts
that doubling the hypoxia causes the survival to be further
reduced by about another 10-fold and this is consistent with
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Figure 5 The modelled relationship between overall surviving
fraction and the proportion of cells killed by a bioreductive drug
for a single dose of 20 Gy X-rays and a single administration of a
bioreductive agent such as SR 4233. The model shows the effect
of different chemosensitive fractions (v) from 0 to 1.0.
the experimental results shown in Figure 2.
Although several assumptions are involved in the model-
ling of the effect of SR 4233 and hypoxic breathing on the
sensitivity of tumours to bioreductive radiotherapy, the pro-
cedure provides a useful way of predicting the effect of
various physiological and pharmacological manoeuvres. For
example comparing Figures 5 and 6 it can be seen that if a
high proportion of hypoxic cells are killed by the administra-
tion of SR 4233 then a much increased effect is achieved in
fractionated compared to single treatment protocols. Also,
increasing the proportion of hypoxic cells by hypoxic
breathing has little effect on a single treatment, but can
considerably enhance the antitumour effectiveness of frac-
tionated protocols.
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Figure 6 The modelled relationship between overall surviving
fraction and the proportion of cells killed by a bioreductive drug
for a fractionated treatment comprising eight fractions of 2.5 Gy
X-rays and a bioreductive agent such as SR 4233. The model
shows the effect of different chemosensitive fractions (') from 0
to 1.0.
Conclusions
The antitumour effectiveness of SR 4233 can be enhanced by
increasing tumour hypoxia via exposure to a reduced oxygen
environment. This manoeuvre causes some increase in
systemic toxicity which may balance part of the improved
antitumour effect, but these experiments clearly suggest that
changing tumour oxygenation can modulate the therapeutic
effect. Since the oxygenation of tumour is unstable and sub-
ject to fluctuations this way of improving the effectiveness of
bioreductive agents may be a promising avenue of investiga-
tion. Modelling of the effectiveness of SR 4233 and hypoxic
breathing is a useful means of understanding the most
profitable ways of optimising its use.
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Appendix
The overall survival after radiation treatments followed by bioreduc-
tive drug treatment can be described by:
SFoveral: = ((SFa + SFb) SFd)'
where SFoveral, is the overall survival of the tumour population and
SFa and SFb represent the survival of the oxic and hypoxic propor-
tions of cells respectively to radiation treatment and SFd represents
the surviving fraction after drug treatment and n is the number of
fractions. This survival can be written in more detail as:
SFoveral := (SFO(I - 4) + SFh-)-(l - (- (1 - SFd))n
where SFO and SFh are the surviving fractions of the
radiobiologically oxic and hypoxic populations respectively given by
linear quadratic model. SFd is the surviving fraction of the
chemotherapeutic hypoxic fraction, b is the radiobiologically
hypoxic fraction, and T the chemotherapeutic hypoxic fraction. The
linear quadratic model SF = e (,D+ DZ) is used to calculate the
model. A hypoxic fraction of 5% has been assumed in this study and
a and P constants of the linear quadratic model for oxic and hypoxic
cells have been assigned values of 0.3, 0.03 and 0.1, 0.0033 respec-
tively, i.e. an O.E.R. of 3. An assumption made in this model is that
complete reoxygenation of this tumour occurs between each fraction.
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